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Background: It has been shown that heat shock-related 70-kDa protein 2 (HSPA2), a member of the HSP70 family
of heat shock proteins, is important for cancer cell growth and metastasis. However, the status of HSPA2 expression
and its prognostic significance in pancreatic cancer remain unknown.
Methods: Quantitative reverse transcriptase ploymerase chain reaction (qRT-PCR) was applied to examine HSPA2
messenger RNA (mRNA) expression in 104 pairs of pancreatic cancer tissues and adjacent noncancerous tissues.
Statistical analyses were applied to evaluate the diagnostic value and associations of HSPA2 expression with
clinicopathological characteristics.
Results: HSPA2 mRNA was significantly overexpressed in pancreatic cancer tissues (3.9 ± 0.8) than in adjacent
normal tissues (1.1 ± 0.4) (P < 0.001). Clinicopathological analysis showed that HSPA2 expression was significantly
correlated with tumor size (P = 0.024), histological differentiation (P = 0.012), TNM stage (P = 0.006), lymph node
metastasis (P = 0.043) and serum CA19-9 level (P = 0.046). Moreover, patients with higher HSPA2 expression levels
had shorter overall survival time than those with lower HSPA2 expression levels (P = 0.019). Furthermore, Cox
regression analyses showed that HSPA2 expression was an independent predictor of overall survival (P = 0.011).
Conclusions: Our results suggest that overexpression of HSPA2 in pancreatic cancer is associated with aggressive
progression and poor prognosis and that HSPA2 may be served as a prognostic marker.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/5988744821527257.
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Pancreatic cancer remains to be one of the most challen-
ging malignancies to treat. Surgical resection offers the
only opportunity for cure. However, as no valid method
for early detection of this disease has been established,
80% or more of patients present with unresectable dis-
ease at the time of diagnosis [1]. Furthermore, even
when resection is performed, the recurrence rate is ex-
tremely high, resulting in the 5-year survival rate of pa-
tients with resected pancreatic cancer being no more
than 20% [2]. Currently, carbohydrate antigen 19–9
(CA19-9) is commonly used for pancreatic cancer detec-
tion. However, the sensitivity and specificity of CA19-9* Correspondence: dr_hui_zhang@163.com
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Therefore, more accurate and acceptable tumor markers
for the early detection of pancreatic cancer are needed.
Heat shock-related 70-kDa protein 2 (HSPA2, also
known as HSP70-2) is a member of the HSP70 family of
heat shock proteins [4]. The HSPA2 gene was originally
characterized as the human counterpart of rodent genes
which are specifically and highly expressed in the testis
[5,6]. Recently, HSPA2 has attracted increased interest
due to its possible involvement in carcinogenesis of non-
testicular tissues. The overexpression of HSPA2 has been
identified in several human malignancies, including non-
small cell lung cancer [7], cervical carcinoma [8],
esophageal squamous cell carcinoma [9], and hepatocel-
lular carcinoma [10]. However, little is known about the
expression and clinical significance of HSPA2 in pancre-
atic cancer. In this study, we therefore assessed theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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series of pancreatic cancer specimens and investigated
its associations with clinicopathological parameters and
overall survival in patients with pancreatic cancer.
Methods
Patients and tissue specimens
A total of 104 consecutive patients with pancreatic
ductal adenocarcinoma who underwent Whipple pro-
cedure at Air Force General Hospital of PLA between
January 2009 and December 2012 were retrospectively
reviewed. None of the patients had received chemother-
apy or radiotherapy before surgery. Fresh tissues includ-
ing pancreatic cancer tissues and adjacent normal tissues
were collected and immediately snap-frozen in liquid ni-
trogen after surgery and were stored at −196°C until
used. Patient preoperative demographic and clinical data,
including age, gender, details of pathological diagnosis,
serum CA 19–9 levels, follow-up period, and overall sur-
vival were collected prospectively. Patients were given
postoperative adjuvant chemotherapy every four weeks
for three months (Gemcitabine 1000 mg/m2 on days 1,
8, and 15). The study has been conducted in accordance
with the ethical standards and the principles of the
Declaration of Helsinki and has been approved by the
Institutional Review Board of Air Force General Hospital
of PLA. Written informed consent was obtained from all
of the patients.
qRT-PCR
Quantitative reverse transcriptase polymerase chain re-
action (qRT-PCR) was utilized to detect HSPA2 expres-
sion in pancreatic cancer tissues. Briefly, total RNA was
extracted using TRIzol extraction liquid (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s in-
structions. β-actin was used as an internal control. The
reverse transcriptase (RT) reaction contained 10 ng of
total RNAs, 50 nmol/l stem-loop RT primer, 1 × RT buf-
fer, 0.25 mmol/l each of deoxynucleotide triphosphate
(dNTP), 3.33U/μl MultiScribe reverse transcriptase, and
0.25U/μl RNase Inhibitor. The 20 μl reaction volumes
were incubated at 16°C for 30 min, 40°C for 30 min, and
85°C for 5 min. Real-time PCR was then performed on a
StepOnePlus real-time PCR system (Applied Biosystems,
Foster City, CA, USA). The sequences of the primers
were as follows: human HSPA2 forward 5’-TTCCACT
CAGGCCGCGTCCG-3’ and reverse 5’-AATCGGGCC
TTGGCAATCGTT-3’ and human β-actin forward 5’-
CAAGAGATGGCCACGGCTGCT-3’ and reverse 5’-
TCCTTCTGCATCTGTCGGCA-3’. The following PCR
parameters were used: 95°C for 2 min, followed by 35 cy-
cles of 95°C for 30 sec and 60°C for 30 sec and a final
elongation step of 72°C for 10 min. All reactions were
performed in triplicate and the cycle threshold (CT)value in each reaction well was recorded. The relative
quantification of HSPA2 mRNA expression was calcu-
lated using the 2-ΔΔCT method.
Statistical analysis
The HSPA2 mRNA expression level was expressed as
mean ± standard deviation (SD). Associations between
HSPA2 mRNA expression level in pancreatic cancer and
clinicopathological features were determined using the
χ2-test. The Kaplan-Meier method was used to estimate
survival rates, and the log-rank test was used to assess
survival differences between groups. The Cox propor-
tional hazards model for multivariate survival analysis
was used to assess predictors related to overall survival.
All statistical analyses were performed using SPSS soft-
ware (SPSS 19.0, Chicago, IL, USA) and P < 0.05 was
considered statistically significant.
Results
HSPA2 mRNA upregulation in pancreatic cancer
The clinicopathological features of all the patients were
summarized in Table 1. The patients were aged from 41
to 86 years with a median of 62 years. The degree of dif-
ferentiation was well differentiated in 13 cases, moder-
ately differentiated in 43 cases, and poorly differentiated
in 48 cases. A total of 29 cases had lymph node metasta-
ses, while the remaining 75 cases did not have lymph
node metastases. The clinical TNM stage according to
the 7th edition of the AJCC cancer staging manual was
27 cases of stage IA, 39 cases of stage IB, 28 cases of
stage IIA, and 10 cases of stage IIB. Serum CA19-9 and
bilirubin were elevated in 77 and 69 patients, respectively.
HSPA2 mRNA expression was detected in 104 pairs of
pancreatic cancer and adjacent normal tissues by real-
time quantitative RT-PCR. As shown in Figure 1, after
normalization to β-actin expression levels, the ex-
pression level of HSPA2 in pancreatic cancer tissues
(3.9 ± 0.8) was significantly higher than that in adjacent
normal tissues (1.1 ± 0.4) (P < 0.001). The median HSPA2
mRNA expression level of pancreatic cancer tissues (4.1)
was used as a cut-off point to divide all 104 patients into
two groups: pancreatic cancer patients who expressed
HSPA2 at levels less than the cut-off value were assigned
to the low expression group (n = 49), and those with
HSPA2 mRNA expression higher than the cut-off value
were assigned to the high expression group (n = 55).
Association between HSPA2 mRNA upregulation and
clinicopathological parameters of patients with
pancreatic cancer
Table 1 summarized the association between HSPA2
mRNA expression and clinicopathological parameters in
pancreatic cancer. HSPA2 mRNA expression levels were
significantly higher in the cancerous tissues of patients
Table 1 Association between HSPA2 mRNA expression
and clinicopathological features of pancreatic cancer
Variables No. of cases
(n = 104)
HSPA2 mRNA expression P-value
Low (n, %) High (n, %)
Age (years) 0.484
<60 43 21 (48.8) 22 (51.2)
≥60 61 28 (44.3) 33 (54.1)
Gender 0.396
Male 82 37 (45.1) 45 (54.9)
Female 22 12 (54.5) 10 (45.5)
Tumor size (cm) 0.024
<2 47 32 (68.1) 15 (31.9)
≥2 57 17 (29.8) 40 (70.2)
Histological grades 0.012
Well/Moderate 56 32 (57.0) 24 (43.0)
Poor 48 17 (35.4) 31 (64.6)
TNM stagea 0.006
IA-IB 66 35 (53.0) 31 (47.0)




No 75 39 (48.0) 36 (52.0)
Yes 29 10 (44.8) 19 (55.2)
Vascular invasion 0.062
No 80 39 (48.8) 41 (51.2)
Yes 24 10 (41.7) 14 (58.3)
CA19-9 (U/ml) 0.046
<27 27 14 (51.9) 13 (48.1)
≥27 77 35 (45.5) 42 (54.5)
Bilirubin (μmol/l) 0.178
<17.1 35 16 (45.7) 19 (54.3)
≥17.1 69 33 (47.8) 36 (52.3)
aTNM staging was classified according to the 7th edition of the AJCC cancer
staging manual.
HSPA2, Heat shock-related 70 kDa protein 2.
Figure 1 Relative expression of HSPA2 in 104 pairs of
pancreatic cancer tissues (C) and adjacent normal tissues (N).
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IB stage (P = 0.006). In addition, HSPA2 mRNA was
expressed at significantly higher levels in patients with
larger tumor sizes (P = 0.024). Moreover, we found that
poorly differentiated tumors expressed higher HSPA2 than
well or moderately differentiated tumors (P = 0.012). Fi-
nally, there were sufficient evidence to confirm its correl-
ation with lymph node metastasis and serum CA19-9 level
in pancreatic cancer (P = 0.043 and P = 0.046, respectively).
Association between HSPA2 mRNA upregulation and
poor prognosis in patients with pancreatic cancer
The association between HSPA2 mRNA expression
and overall survival of pancreatic cancer patients wasinvestigated by Kaplan-Meier analysis and log-rank
test. During the follow-up period, 81 of the 104 patients
(77.9%) died. As shown in Figure 2, pancreatic cancer pa-
tients with low HSPA2 mRNA expression level had longer
overall survival time than those with high HSPA2 mRNA
expression level (log-rank test: P =0.019). Univariate ana-
lysis demonstrated that TNM stage (P = 0.013), the status
of lymph node metastasis (P = 0.040) and vascular in-
vasion (P = 0.017), and HSPA2 mRNA expression
level (P = 0.007) were significantly associated with overall
survival of pancreatic cancer patients (Table 2). No sig-
nificant associations with patient survival were found
among age at diagnosis, gender, tumor size, histological
grade, serum CA19-9 level, and bilirubin. Multivariate
analysis using the Cox proportional hazards model for all
variables that were significant in the univariate analysis
showed that TNM stage (P = 0.026), the status of vascular
invasion (P = 0.042), and HSPA2 mRNA expression level
(P = 0.011) were independent prognostic factors for over-
all survival in patients with pancreatic cancer (Table 2).
Discussion
HSPA2, as a testis-specific protein, played an important
role in spermatogenesis [5,6]. Recently, research has
shown that human tumor cells can express HSPA2 at
high levels [11,12]. The polymorphism of HSPA2 at pos-
ition 1267 has been suggested to be associated with car-
cinogenesis in several malignant cancer tissues, such as
lung cancer, cervical cancer, esophageal squamous cell
carcinoma, and hepatocellular carcinoma [7-10]. Previ-
ous study has shown that HSPA2 was not found in nor-
mal pancreas [13]. However, whether HSPA2 is highly
expressed in pancreatic cancer is unclear. For a more
comprehensive insight into the clinical value of HSPA2
in pancreatic cancer, we performed a real-time quantitative
Figure 2 Kaplan-Meier survival analysis for high HSPA2 mRNA expression level versus low HSPA2 mRNA expression level in patients
with pancreatic cancer.
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HSPA2 as well as to investigate its association with
clinicopathological features of pancreatic cancer pa-
tients. Our data revealed that the mRNA expression
level of HSPA2 was significantly upregulated in pancre-
atic ductal adenocarcinoma and its expression wasTable 2 Univariate and multivariate analyses of




HR (95% CI) P-value
Age at diagnosis (years)
<60 vs. ≥60 0.584
Gender
Male vs. Female 0.763
Tumor size (cm)
<2 vs. ≥2 0.082
Histological grades
Well/Moderate vs. Poor 0.067
TNM stagea
IA-IB vs. IIA-IIB 0.013 1.23 (1.14-1.52) 0.026
Lymph node metastasis
No vs. Yes 0.040 1.14 (0.97-1.41) 0.054
Vascular invasion
No vs. Yes 0.017 1.27 (1.04-1.49) 0.042
CA19-9 (U/ml)
<27 vs. ≥27 0.082
Bilirubin (μmol/l)
<17.1 vs. ≥17.1 0.185
HSPA2 mRNA expression
Low vs. High 0.007 1.58 (1.11-1.89) 0.011
aTNM staging was classified according to the 7th edition of the AJCC cancer
staging manual.
HSPA2, Heat shock-related 70 kDa protein 2.correlated with tumor size, tumor differentiation, TNM
stage, lymph node metastasis, and serum CA19-9 levels.
More importantly, we also demonstrated that the
mRNA expression of HSPA2 was an independent prog-
nostic predictor for overall survival.
Ductal adenocarcinoma is the most common type of
pancreatic cancer, accounting for over 85% of cases [14].
It is the fourth leading cause of cancer death in the
United States with a median survival of less than
6 month and a dismal 5-year survival rate of 3%-5% [15].
The cancer’s lethal nature stems from its propensity to
rapidly disseminate to the lymphatic system and distant
organs [16]. This aggressive biology and resistance to
conventional and targeted therapeutic agents leads to a
typical clinical presentation of incurable disease at the
time of diagnosis. In the current study, we found that
HSPA2 expression was proved to be associated with
tumor size, histologic grade, tumor stage, and lymph
node metastasis, strongly suggesting that HSPA2 might
be involved in the carcinogenesis, development, progres-
sion, and metastasis of pancreatic ductal adenocarcin-
oma. More importantly, we proved that HSPA2 mRNA
expression was significantly associated with overall sur-
vival of patients with pancreatic cancer. In support of
this, Kaplan-Meier analysis of overall survival showed
that patients whose tumors had higher HSPA2 expres-
sion tend to have a significantly worse overall survival,
indicating that a high HSPA2 level is a marker of poor
prognosis for patients with pancreatic cancer. Moreover,
the Cox proportional hazards model showed that HSPA2
was a marker of poor overall survival independent of the
known clinical prognostic indicators such as TNM stage
and vascular invasion. Therefore, it could constitute a
molecular prognostic marker for these patients, identify-
ing who are more likely to have higher risk of death;
thus, good candidates are to receive more aggressive
treatments.
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In summary, we have reported the differential expression
of HSPA2 in pancreatic cancer and adjacent normal tis-
sues. Our results suggest that high expression of HSPA2
in pancreatic cancer is associated with poor overall sur-
vival and that HSPA2 may be served as a prognostic
marker for pancreatic cancer.
Abbreviations
CA19-9: Carbohydrate antigen 19–9; CT: Cycle threshold; dNTP: Deoxynucleotide
triphosphate; HSPA2: Heat shock-related 70-kDa protein 2; mRNA: messenger
RNA; qRT-PCR: Quantitative reverse-transcription polymerase chain reaction;
RT: Reverse transcriptase; SD: standard deviation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HZ and HLG carried out the qRT-PCR experiments and drafted the manuscript.
CLL and YLK collected the clinical data. CW participated in the design of the
study and performed the statistical analysis. HYZ conceived of the study, and
participated in its design and coordination and helped to draft the manuscript.
All authors have read and approved the final manuscript.
Acknowledgments
This work was supported by a grant from the National Natural Science
Foundation of China (No. 87430025). We thank the LetPub language editing
company for their excellant language editing work for this manuscript.
Author details
1Department of Hepatobiliary Surgery, Air Force General Hospital of PLA,
Beijing 100142, China. 2Department of Oncology, the fourth people’s hospital
of Jinan, Jinan 250031, China.
Received: 7 December 2014 Accepted: 17 March 2015
References
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin.
2012;62:10–29.
2. Liao WC, Chien KL, Lin YL, Wu MS, Lin JT, Wang HP, et al. Adjuvant
treatments for resected pancreatic adenocarcinoma: a systematic review
and network meta-analysis. Lancet Oncol. 2013;14:1095–103.
3. Jin XL, Xu B, Wu YL. Detection of pancreatic cancer with normal
carbohydrate antigen 19–9 using protein chip technology. World J
Gastroenterol. 2014;20:14958–64.
4. Bonnycastle LL, Yu CE, Hunt CR, Trask BJ, Clancy KP, Weber JL, et al. Cloning,
sequencing, and mapping of the human chromosome 14 heat shock
protein gene (HSPA2). Genomics. 1994;23:85–93.
5. Dix DJ, Allen JW, Collins BW, Poorman-Allen P, Mori C, Blizard DR, et al.
HSP70-2 is required for desynapsis of synaptonemal complexes during
meiotic prophase in juvenile and adult mouse spermatocytes. Development.
1997;124:4595–603.
6. Dix DJ, Allen JW, Collins BW, Mori C, Nakamura N, Poorman-Allen P, et al.
Targeted gene disruption of Hsp70-2 results in failed meiosis, germ cell
apoptosis, and male infertility. Proc Natl Acad Sci U S A. 1996;93:3264–8.
7. Scieglinska D, Gogler-Piglowska A, Butkiewicz D, Chekan M, Malusecka E,
Harasim J, et al. HSPA2 is expressed in human tumors and correlates with
clinical features in non-small cell lung carcinoma patients. Anticancer Res.
2014;34:2833–40.
8. Garg M, Kanojia D, Saini S, Suri S, Gupta A, Surolia A, et al. Germ cell-specific
heat shock protein 70–2 is expressed in cervical carcinoma and is involved
in the growth, migration, and invasion of cervical cells. Cancer.
2010;116:3785–896.
9. Zhang H, Chen W, Duan CJ, Zhang CF. Overexpression of HSPA2 is
correlated with poor prognosis in esophageal squamous cell carcinoma.
World J Surg Oncol. 2013;11:141.10. Fu Y, Zhao H, Li XS, Kang HR, Ma JX, Yao FF, et al. Expression of HSPA2 in
human hepatocellular carcinoma and its clinical significance. Tumour Biol.
2014;35:11283–7.
11. Rohde M, Daugaard M, Jensen MH, Helin K, Nylandsted J, Jaattela M.
Members of the heat-shock protein 70 family promote cancer cell growth
by distinct mechanisms. Genes Dev. 2005;19:570–82.
12. Scieglinska D, Piglowski W, Mazurek A, Malusecka E, Zebracka J, Filipczak P,
et al. The HspA2 protein localizes in nucleoli and centrosomes of heat
shocked cancer cells. J Cell Biochem. 2008;104:2193–206.
13. Scieglinska D, Piglowski W, Chekan M, Mazurek A, Krawczyk Z. Differential
expression of HSPA1 and HSPA2 proteins in human tissues; tissue
microarray-based immunohistochemical study. Histochem Cell Biol.
2011;135:337–50.
14. Ottenhof NA, de Wilde RF, Maitra A, Hruban RH, Offerhaus GJ. Molecular
characteristics of pancreatic ductal adenocarcinoma. Patholog Res Int.
2011;2011:620601.
15. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics
and biology of pancreatic ductal adenocarcinoma. Genes Dev.
2006;20:1218–49.
16. La Torre M, Nigri G, Petrucciani N, Cavallini M, Aurello P, Cosenza G, et al.
Prognostic assessment of different lymph node staging methods for
pancreatic cancer with R0 resection: pN staging, lymph node ratio, log odds
of positive lymph nodes. Pancreatology. 2014;14:289–94.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
